These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19722724)

  • 1. Public perceptions of the pharmaceutical industry and drug safety: implications for the pharmacovigilance professional and the culture of safety.
    Olsen AK; Whalen MD
    Drug Saf; 2009; 32(10):805-10. PubMed ID: 19722724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
    Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
    Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Internet and drug safety: what are the implications for pharmacovigilance?
    Cobert B; Silvey J
    Drug Saf; 1999 Feb; 20(2):95-107. PubMed ID: 10082068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacists' knowledge of the safety of antibiotics for systemic use.
    Yakimova Y
    Int J Risk Saf Med; 2015; 27 Suppl 1():S11-2. PubMed ID: 26639686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing stakeholder opinion on relations between cancer patient groups and pharmaceutical companies in Europe.
    Leto di Priolo S; Fehervary A; Riggins P; Redmond K
    Patient; 2012; 5(2):127-39. PubMed ID: 22299759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History, status, and politicization of the FDA.
    Wang W; Wertheimer AI
    Res Social Adm Pharm; 2022 May; 18(5):2811-2816. PubMed ID: 34215537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of medicines-Pharmacists' knowledge, practice, and attitudes toward pharmacovigilance and adverse drug reactions reporting process.
    Kopciuch D; Zaprutko T; Paczkowska A; Ratajczak P; Zielińska-Tomczak Ł; Kus K; Nowakowska E
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1543-1551. PubMed ID: 31148344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What influences healthcare providers' prescribing decisions? Results from a national survey.
    Price SM; O'Donoghue AC; Rizzo L; Sapru S; Aikin KJ
    Res Social Adm Pharm; 2021 Oct; 17(10):1770-1779. PubMed ID: 33558154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principles and Considerations for Responsible Sharing of Safety Information Via the Medical Information Channel.
    Hristoskova S; Milligan J; De Wit J; Pesonen J; Rennick R;
    Ther Innov Regul Sci; 2020 Jul; 54(4):939-946. PubMed ID: 32557314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European pharmacovigilance: increasingly outsourced to drug companies.
    Prescrire Int; 2014 Dec; 23(155):302-3, 305-7. PubMed ID: 25629153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient literacy and awareness of medicine safety.
    See M; Butcher BE; Banh A
    Int J Pharm Pract; 2020 Dec; 28(6):552-560. PubMed ID: 32931060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
    Matos C; van Hunsel F; Joaquim J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
    Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
    Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicine safety: experiences and perceptions of the general public in Liverpool.
    Krska J; Jones L; McKinney J; Wilson C
    Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1098-103. PubMed ID: 21809408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics.
    Kaguelidou F; Durrieu G; Clavenna A
    Therapie; 2019 Apr; 74(2):315-324. PubMed ID: 30773345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.